Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS.
Gordon PH, Cheung YK, Levin B, Andrews H, Doorish C, Macarthur RB, Montes J, Bednarz K, Florence J, Rowin J, Boylan K, Mozaffar T, Tandan R, Mitsumoto H, Kelvin EA, Chapin J, Bedlack R, Rivner M, McCluskey LF, Pestronk A, Graves M, Sorenson EJ, Barohn RJ, Belsh JM, Lou JS, Levine T, Saperstein D, Miller RG, Scelsa SN; Combination Drug Selection Trial Study Group. Gordon PH, et al. Among authors: mccluskey lf. Amyotroph Lateral Scler. 2008 Aug;9(4):212-22. doi: 10.1080/17482960802195632. Amyotroph Lateral Scler. 2008. PMID: 18608093 Free PMC article. Clinical Trial.
Venous thrombosis in an ALS population over four years.
Elman LB, Siderowf A, Houseman G, Kelley M, McCluskey LF. Elman LB, et al. Among authors: mccluskey lf. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005 Dec;6(4):246-9. doi: 10.1080/14660820510043226. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005. PMID: 16319029
Subcutaneous IGF-1 is not beneficial in 2-year ALS trial.
Sorenson EJ, Windbank AJ, Mandrekar JN, Bamlet WR, Appel SH, Armon C, Barkhaus PE, Bosch P, Boylan K, David WS, Feldman E, Glass J, Gutmann L, Katz J, King W, Luciano CA, McCluskey LF, Nash S, Newman DS, Pascuzzi RM, Pioro E, Sams LJ, Scelsa S, Simpson EP, Subramony SH, Tiryaki E, Thornton CA. Sorenson EJ, et al. Among authors: mccluskey lf. Neurology. 2008 Nov 25;71(22):1770-5. doi: 10.1212/01.wnl.0000335970.78664.36. Neurology. 2008. PMID: 19029516 Free PMC article. Clinical Trial.
Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design.
Miller RG, Moore DH, Forshew DA, Katz JS, Barohn RJ, Valan M, Bromberg MB, Goslin KL, Graves MC, McCluskey LF, McVey AL, Mozaffar T, Florence JM, Pestronk A, Ross M, Simpson EP, Appel SH; WALS Study Group. Miller RG, et al. Among authors: mccluskey lf. Neurology. 2011 Sep 6;77(10):973-9. doi: 10.1212/WNL.0b013e31822dc7a5. Epub 2011 Aug 3. Neurology. 2011. PMID: 21813790 Free PMC article. Clinical Trial.
Design and Statistical Innovations in a Platform Trial for Amyotrophic Lateral Sclerosis.
Quintana M, Saville BR, Vestrucci M, Detry MA, Chibnik L, Shefner J, Berry JD, Chase M, Andrews J, Sherman AV, Yu H, Drake K, Cudkowicz M, Paganoni S, Macklin EA; HEALEY ALS Platform Trial Study Group. Quintana M, et al. Ann Neurol. 2023 Sep;94(3):547-560. doi: 10.1002/ana.26714. Epub 2023 Jun 22. Ann Neurol. 2023. PMID: 37245090
Recurrent migraine and intravenous immune globulin therapy.
Constantinescu CS, Chang AP, McCluskey LF. Constantinescu CS, et al. Among authors: mccluskey lf. N Engl J Med. 1993 Aug 19;329(8):583-4. doi: 10.1056/NEJM199308193290820. N Engl J Med. 1993. PMID: 8336767 No abstract available.
38 results